Evercore ISI Group Cuts argenx (ARGX) Price Target to $1,078

Evercore ISI Group has reiterated its Outperform rating on argenx SE while adjusting its price target significantly downward, a 29.77% upside from the current price.

By TradeTexts Research Desk · Published Oct 16, 2026, 2:06 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Evercore ISI Group cut its price target on argenx SE ($ARGX) to $1,078 from $1,175 on October 9, 2026, and rates the stock "Outperform".

Since the rating, $ARGX is down 0.7% after 1 week and down 0.7% to date (from the $825.03 close on Oct 9, 2026).

ARGX argenx SE

$819.14 -2.48% year to date

Daily close · Oct 16, 2026

Key Points

On October 9, 2026, Evercore ISI Group reiterated its Outperform rating on argenx SE and lowered the price target from $1175 to $1078.
Evercore ISI Group's $1,078 price target implies 29.77% upside from argenx SE's ($ARGX) current $830.71 share price.
As of October 16, 2026, argenx SE is trading around $830.71, which is about 22.9% below the new target.
The company is set to report earnings on October 22, 2026, after a year with a revenue growth of 59.3%.

Get $ARGX trade alerts by text

We text you when insiders, Congress or big funds trade $ARGX. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated argenx SE alert may contain errors. Disclosures

Evercore ISI Group has reiterated its Outperform rating on argenx SE (NasdaqGS: ARGX) and adjusted the price target down from $1175 to $1078 on October 9, 2026. This change comes as the stock trades at $830.71, roughly 22.9% below the new target price.

Other Institutional Activity in argenx SE

Several other institutional investors have recently adjusted their positions in argenx SE. FMR, LLC holds 5,231,452 shares valued at about $4.29 billion after adding 240,561 shares, a 4.8% increase. Jupiter Topco LLC saw significant growth, increasing its holdings by 1,237,008 shares to a total of 2,474,015 shares worth about $2.03 billion. In contrast, Price (T.Rowe) Associates Inc reduced its stake by 696,933 shares, ending with 2,678,047 shares valued at approximately $2.19 billion, a decrease of 20.6%.

argenx SE Stock Down 16.1%

Currently, argenx SE's shares are trading well below the new price target set by Evercore ISI Group. The stock closed at a price of $830.71 as of October 16, 2026. This level is significantly below the target, indicating potential volatility ahead as the market reacts to the adjusted outlook.

12-month forecast

$ARGX price target

argenx SE daily closes and this analyst's $1,078 target. Not advice.

Recent Earnings

For the trailing twelve months, argenx SE reported a revenue of about $5.32 billion and an EPS of $26.22. The company has experienced a strong revenue growth of 59.3% year-over-year, showcasing its solid position in the biotechnology sector. The next earnings report is expected on October 22, 2026.

Analysts Set New Price Targets

On October 9, 2026, Evercore ISI Group maintained its Outperform rating on argenx SE with a revised price target of $1078, down from $1175. Additionally, Morgan Stanley maintained an Overweight rating with a target of $1250 on August 31, 2026, while Wedbush reiterated its Outperform rating with a consistent target of $1150 on September 3 and September 8, 2026. The consensus among analysts suggests a positive outlook, with a mean price target that indicates potential upside from current trading levels.

About argenx SE

argenx SE is a biotechnology company based in Amsterdam, Netherlands. It focuses on developing therapies for autoimmune diseases. Its key products include VYVGART, which treats generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP), and VYVGART HYTRULO, aimed at treating gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).

Bottom Line

Investors should keep an eye on argenx SE as it prepares to report earnings on October 22, 2026. The recent price target adjustments from Evercore ISI Group and other analysts reflect the ongoing assessment of the company’s potential in a competitive market.